Mesenchymal Stem Cell Therapy for Hepatic Encephalopathy Due to Advance Liver Cirrhosis: Case Study
Article Sidebar
Main Article Content
Abstract
Mesenchymal stem cell (MSC) transplantation may be an alternative to liver transplantation for patients with end-stage liver disease. A 24-year-old patient with Hepatic Encephalopathy due to alcoholic liver cirrhosis underwent UCMSC transplantation because there were no donors available for liver transplants involving adult deceased and living individuals. The patient was given allogeneic Umbilical cord-derived MSCs, which were then cultured following accepted practices. Subsequently, the UCMSCs were infused through the intravenous route 3 times at the interval of 30 days. Serum bilirubin, globulin, and ammonia levels were improved after the infusion and the morphology of the liver and spleen had also improved.
Article Details
Copyright (c) 2024 Patel M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Geiger A, Magnes J, Taylor Rm, Veralli M. Effect of blood constituents on uptake of glucose and on metabolic rate of the brain in perfusion experiments. Am J Physiol. 1954;177(1):138-149. Available from: https://doi.org/10.1152/ajplegacy.1954.177.1.138
Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008;49(5):845-61. Available from: https://doi.org/10.1016/j.jhep.2008.08.009
Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003;23(3):259-69. Available from: https://doi.org/10.1055/s-2003-42644
Wright G, Sharifi Y, Jover-Cobos M, Jalan R. The brain in acute on chronic liver failure. Metab Brain Dis. 2014;29(4):965-73. Available from: https://doi.org/10.1007/s11011-014-9553-0
Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114(3):188-93. Available from: https://doi.org/10.1016/S0002-9343(02)01477-8.
Vierling JM. Masoud Mokhtarani, Robert S. Brown Jr., Parvez Mantry, Don C. Rockey, Marwan Ghabril et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2016;14:903-906.e901. https://doi.org/10.1016/j.cgh.2015.11.018
Hu, C. Kaizhou Huang, Lingfei Zhao, Fen Zhang, Zhongwen Wu & Lanjuan Li, et al. Serum ammonia is a strong prognostic factor for patients with acute-on-chronic liver failure. Sci. Rep. 2020;10: 16970. https://doi.org/10.1038/s41598-020-73603-1
Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic Role of Ammonia in Patients With Cirrhosis. Hepatology. 2019;70(3):982-994. Available from: https://doi.org/10.1002/hep.30534
Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217(2):318-24. Available from: https://doi.org/10.1002/path.2469
Patel M, Patel A, Kshatriya P. Subcutaneous and Intravenous Administration of Human Umbilical Cord Mesenchymal Stem Cells in Patient with Multiple Foot Ulcers Complicated by Scleroderma- A Case Report with One Year Follow Up. J Reg Med Biol Res. 2023;4(3):1-6. Available from: https://doi.org/10.46889/JRMBR.2023.4302
Wijdicks EF. Hepatic Encephalopathy. N Engl J Med. 2016;375(17):1660-1670. Available from: https://doi.org/10.1056/nejmra1600561
Moore JK, Stutchfield BM, Forbes SJ. Systematic review: the effects of autologous stem cell therapy for patients with liver disease. Aliment Pharmacol Ther. 2014;39(7):673-685. Available from: https://doi.org/10.1111/apt.12645
Pan XN, Zheng LQ, Lai XH. Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis. World J. Gastroenterol. 2014;20:14051-14057. Available from: https://doi.org/10.3748%2Fwjg.v20.i38.14051
Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med. 2018;7(9):651-663. Available from: https://doi.org/10.1002/sctm.18-0024
Sisakhtnezhad S, Alimoradi E, Akrami H. External factors influencing mesenchymal stem cell fate in vitro. Eur J Cell Biol. 2017;96(1):13-33. Available from: https://doi.org/10.1016/j.ejcb.2016.11.003
Saleh M, Taher M, Sohrabpour AA, Vaezi AA, Nasiri Toosi M, Kavianpour M, et al. Perspective of placenta derived mesenchymal stem cells in acute liver failure. Cell Biosci. 2020;10:71. Available from: https://doi.org/10.1186%2Fs13578-020-00433-z
Eom YW, Kang SH, Kim MY, Lee JI, Baik SK. Mesenchymal stem cells to treat liver diseases. Ann Transl Med. 2020;8(8):563. Available from: https://doi.org/10.21037%2Fatm.2020.02.163
Mäkelä T, Takalo R, Arvola O, Haapanen H, Yannopoulos F, Blanco R, et al. Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model. Cytotherapy. 2015;17(4):392-402. Available from: https://doi.org/10.1016/j.jcyt.2014.12.004
Kim I, Bang SI, Lee SK, Park SY, Kim M, Ha H. Clinical implication of allogenic implantation of adipogenic differentiated adipose-derived stem cells. Stem Cells Transl Med. 2014;3(11):1312-1321. Available from: https://doi.org/10.5966%2Fsctm.2014-0109